MMP-2 and TIMP-2 in cutaneous melanoma: Association with prognostic factors and description in cutaneous metastases

American Journal of Dermatopathology

Volumn 33, Issue 4, 2011, Pages 413-414

  Rey, Maria Carolina W ^a   Bonamigo, Renan R ^a   Cartell, André ^a   Furian, Roque ^a   Bonfá, Raquel ^a   Bonfá, Rafael ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AGE DISTRIBUTION; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SKIN METASTASIS; TUMOR CELL;

AGE FACTORS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79958247987     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181e2e8d6     Document Type: Letter

References (2)

1. Redondo P, Lloret P, Idoate M, et al. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 2005;30:541-545. (Pubitemid 41076024)
2. Väisänen AH, Kallioinen M, Turpeenniemi- Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol. 2008;39:377-385.